Gingival recessions are vastly prevalent among the general population. With regards to their treatment, recent advancements in periodontal and microsurgical procedures, focusing on minimal invasiveness and patient‐centered therapies, have propelled a shift in their contemporary treatment, highlighting the field of biologics and bioactive mediators. Among different classes and types of biologics, autologous platelet concentrates (APCs), also referred to as autologous blood‐derived products, are commonly used and preferred among many clinicians. These are essentially obtained via venipuncture (intravenous access) followed by centrifugation, for which numerous protocols and preparation methods have been used, leading to varieties of blood‐derived products. In this review, via a systematic search, we explored the efficacy of the different utilized preparation methods and centrifugation protocols of APCs (e.g., platelet‐rich plasma (PRP), platelet‐rich fibrin (PRF), leucocyte‐PRF, advanced‐PRF, concentrated growth factor (CGF), etc.) for the treatment of type 1 gingival recessions (RT1, without interproximal attachment loss or noticeable tooth displacement), as well as their effectiveness relative to a common control (treatment with flap advancement alone without any additional material). Based on the available literature from randomized trials found in our systematic search, we observed that utilization of PRF can significantly enhance treatment outcomes when performing a coronally advanced flap, in terms of the amount of root coverage. The improvement in root coverage was further enhanced in the presence of baseline keratinized tissue width, and with an increasing relative magnitude (the more the baseline keratinized tissue width, the better the root coverage outcomes when using PRF). The efficacy of these products needs to be further explored with different graft substitutes and matrices, as well as relative to other commonly applied biologics, through well‐conducted and adequately‐powered randomized clinical trials.

中文翻译：

---

根部覆盖手术中的自体血小板浓缩物


牙龈退缩在普通人群中非常普遍。在治疗方面，牙周和显微外科手术的最新进展，专注于微创和以患者为中心的疗法，推动了他们现代治疗的转变，突出了生物制剂和生物活性介质领域。在不同类别和类型的生物制剂中，自体血小板浓缩物 （APC），也称为自体血源性产品，是许多临床医生常用和首选的产品。这些基本上是通过静脉穿刺（静脉通路）然后离心获得的，为此已经使用了许多方案和制备方法，从而产生了各种血液衍生产品。在本综述中，通过系统检索，我们探讨了 APC 的不同使用的制备方法和离心方案（例如，富血小板血浆 （PRP）、富血小板纤维蛋白 （PRF）、白细胞 PRF、晚期 PRF、浓缩生长因子 （CGF） 等）治疗 1 型牙龈退缩（RT1，无邻间附着丢失或明显的牙齿移位）， 以及它们相对于共同对照的有效性（单独使用皮瓣前移治疗，无需任何其他材料）。根据我们系统搜索中发现的随机试验的现有文献，我们观察到在进行冠状前皮瓣时，就牙根覆盖量而言，使用 PRF 可以显着提高治疗结果。 在基线角化组织宽度存在的情况下，根覆盖率的改善进一步增强，并且相对量级增加（基线角化组织宽度越多，使用 PRF 时根部覆盖结果越好）。这些产品的疗效需要通过实施良好且有足够把握度的随机临床试验，使用不同的移植物替代品和基质，以及相对于其他常用生物制剂的疗效进行进一步探索。